Latest Content

These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.

Two sisters discover they share a BRCA2 mutation, but choose different paths to manage their breast cancer risk and navigate life as previvors.

After 18 years with multiple myeloma, Sally Kalksma shares 10 people, places and things that helped her stay strong through cancer treatment.

In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.

Lyrfigtu was approved for adults with previously treated cholangiocarcinoma with an FGFR2 gene fusion or other rearrangement.

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.

Mindfulness-based cancer recovery and Tai Chi/Qigong improved fatigue and how much pain interfered with daily life among cancer survivors experiencing distress, while Tai Chi/Qigong also improved sleep quality.

A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.

AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.